JP2010501479A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501479A5
JP2010501479A5 JP2009524014A JP2009524014A JP2010501479A5 JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5 JP 2009524014 A JP2009524014 A JP 2009524014A JP 2009524014 A JP2009524014 A JP 2009524014A JP 2010501479 A5 JP2010501479 A5 JP 2010501479A5
Authority
JP
Japan
Prior art keywords
arg
amino acid
shows
amino acids
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009524014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501479A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075728 external-priority patent/WO2008019395A2/en
Publication of JP2010501479A publication Critical patent/JP2010501479A/ja
Publication of JP2010501479A5 publication Critical patent/JP2010501479A5/ja
Pending legal-status Critical Current

Links

JP2009524014A 2006-08-10 2007-08-10 学習および記憶を改善するための化合物 Pending JP2010501479A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83703006P 2006-08-10 2006-08-10
US91747607P 2007-05-11 2007-05-11
PCT/US2007/075728 WO2008019395A2 (en) 2006-08-10 2007-08-10 Compounds for improving learning and memory

Publications (2)

Publication Number Publication Date
JP2010501479A JP2010501479A (ja) 2010-01-21
JP2010501479A5 true JP2010501479A5 (enExample) 2010-07-01

Family

ID=39033625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524014A Pending JP2010501479A (ja) 2006-08-10 2007-08-10 学習および記憶を改善するための化合物

Country Status (6)

Country Link
US (1) US20080108568A1 (enExample)
EP (1) EP2061314A4 (enExample)
JP (1) JP2010501479A (enExample)
AU (1) AU2007281701A1 (enExample)
CA (1) CA2659289A1 (enExample)
WO (1) WO2008019395A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7993836B2 (en) * 2006-01-27 2011-08-09 Translational Genomics Research Institute Genes affecting human memory performance
WO2009151845A1 (en) * 2008-05-12 2009-12-17 Amnestix, Inc. Compounds for rho kinase inhibition and for improving learning and memory
WO2010132128A1 (en) * 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
EP2354789A1 (en) * 2010-02-08 2011-08-10 Sygnis Bioscience GmbH & Co. KG Method for the identification of memory modulating compounds by assessing KIBRA expression
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
US8927498B2 (en) * 2010-07-09 2015-01-06 The Translational Genomics Research Institute Compositions and methods useful in enhancement of memory
WO2013041238A1 (en) * 2011-09-21 2013-03-28 Sygnis Bioscience Gmbh & Co. Kg Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
CN108024753B (zh) 2015-10-27 2021-08-13 赫尔实验室有限公司 程序记忆增强系统和方法，以及计算机可读介质
US11587644B2 (en) 2017-07-28 2023-02-21 The Translational Genomics Research Institute Methods of profiling mass spectral data using neural networks
CA3162382A1 (en) 2020-01-09 2021-07-15 Thomas Macallister Methods of treating cortical dementia associated wandering
EP4125879A4 (en) 2020-03-25 2024-04-03 Woolsey Pharmaceuticals, Inc. METHODS FOR TREATING PROTEINOPATHY-ASSOCIATED WALKING
CN115996728A (zh) * 2020-04-23 2023-04-21 乌尔塞制药公司 利用Rho激酶抑制剂治疗阿尔茨海默病的方法
EP4164652A4 (en) * 2020-06-15 2024-07-10 Woolsey Pharmaceuticals, Inc. METHODS OF USING RHO-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DEMENTIA
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
CN112010805B (zh) * 2020-08-26 2023-12-05 山东威高药业股份有限公司 一种盐酸法舒地尔的精制方法
US20230321114A1 (en) * 2020-08-27 2023-10-12 Woolsey Pharmaceuticals, Inc. Methods of treating age-related cognitive decline
US20230310447A1 (en) * 2020-08-28 2023-10-05 Woolsey Pharmaceuticals, Inc. Methods of treating age-related cognitive decline
US11311553B1 (en) 2020-10-22 2022-04-26 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN114457154B (zh) * 2022-04-13 2022-06-28 山东第一医科大学附属省立医院(山东省立医院) KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993054A (ja) * 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
EP0870767B1 (en) * 1995-07-03 2000-02-16 Asahi Kasei Kogyo Kabushiki Kaisha 1-(5-isoquinolinesulfonyl)homopiperazine hydrochloride hydrates
CA2334120C (en) * 1998-08-10 2006-10-17 Asahi Kasei Kogyo Kabushiki Kaisha Oral sustained-release preparation of fasudil hydrochloride
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US20020173535A1 (en) * 2001-02-07 2002-11-21 Renshaw Perry F. Cholesterol-lowering agents as treatment for psychological and cognitive disorders
ATE439797T1 (de) * 2001-04-27 2009-09-15 Cold Spring Harbor Lab Linderung der gedächtnisdefizite und gedächtniskomponenten von psychiatrischen funktionsstírungen durch veränderung der atypischen pkm-aktivität
DE10153605A1 (de) * 2001-11-02 2003-05-28 Morphochem Ag Komb Chemie Verwendung von Inhibitoren der Rho-Kinasen zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
US7993836B2 (en) * 2006-01-27 2011-08-09 Translational Genomics Research Institute Genes affecting human memory performance
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Similar Documents

Publication Publication Date Title
JP2010501479A5 (enExample)
US12558324B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
US20220117967A1 (en) Compositions and Methods for the Treatment of Prader-Willi Syndrome
US8088951B2 (en) Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
US9402826B2 (en) Neuronal pain pathway modulators
US20210277478A1 (en) Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
CN109475539B (zh) 帕金森氏病的治疗
JP2007529421A5 (enExample)
US10676747B2 (en) Methods for improving cognitive function via modulation of quinone reductase 2
CN107249583A (zh) 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂
JP2012508249A5 (enExample)
JP2011518168A5 (enExample)
JP2023088996A (ja) 癌治療
JP2007527859A (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
US20060167026A1 (en) Antipsychotic molecular-targeting epithelial growth factor receptor
PT1926483E (pt) Tratamento de doenças autoimunes
JP2024543963A (ja) 高い安定性及び遺伝子サイレンシング活性を有する低分子干渉ｒｎａ分子のための修飾パターン
KR20220035275A (ko) 다발성 골수종 치료
WO2003084542A1 (en) Neurotrophic factor production accelerator
JP2008520649A (ja) グリコーゲンシンターゼキナーゼ−３阻害剤
Perveen et al. Charcot-Marie-Tooth type 1A disease from patient to laboratory
US20140080787A1 (en) Method for the Treatment of Neuropathies Associated with Charcot-Marie-Tooth 1A (CMT1A) Disease
US20230285346A1 (en) Methods of using fto inhibitors for the treatment of pulmonary hypertension
JP2013526587A (ja) 大環状化合物および治療方法
US20140130191A1 (en) Methods for treating immune-mediated diseases of the nervous system administering a compound comprising agents that inhibit prokineticin receptors activity